reports
- Thijs Berkelder
- ING Helpdesk
- Jacob Mekhael
Galapagos GLPG3667 phase 2 hits topline in DM, but misses in SLE
Galapagos announced the topline results from 2 phase 2 studies evaluating the efficacy and safety of GLPG3667 (TYK2 inhibitor) in dermatomyositis (DM, GALARISSO study) and active systemic lupus erythematosus (SLE, GALACELA study). The GALARISSO study in DM met its primary endpoint showing a 14.26 delta on the TIS measure at 24 weeks, which compares favourably to brepocitinib (TYK2/JAK1 inhibitor) in our view. In the GALACELA study in SLE patients, primary endpoint at 32 weeks was not met, but fi...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Lewi
Bekaert - Update on the Share Buyback Program and Liquidity Agreement
Bekaert - Update on the Share Buyback Program and Liquidity Agreement Update on the Share Buyback Program and the Liquidity Agreement Period from 11 December 2025 to 17 December 2025 Share Buyback ProgramOn , Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 25 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 11 December 2025 to 17 December 2025, Kepler Cheuvreux SA on behalf of Bekaert has bought 50 000 shares. Th...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquid...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquiditeitsovereenkomst Update over het Inkoopprogramma van Eigen Aandelen en de Liquiditeitsovereenkomst Periode van 11 december 2025 tot 17 december 2025 Inkoopprogramma van Eigen AandelenOp , kondigde Bekaert de start aan van de volgende tranche van haar inkoopprogramma, voor een totaalbedrag van maximaal € 25 miljoen. Zoals eerder aangekondigd heeft het inkoopprogramma tot doel alle ingekochte aandelen te vernietigen. Bekaert kondigt vandaag aan dat gedurende de periode van 11 december 2025 tot 17 december 2025, Kepler...
Bekaert: Transparency Law
Bekaert: Transparency Law Transparency LawDisclosure in accordance with the Law of 2 May 2007 Pursuant to Articles 15 §1 and 18 §1 of the Law of 2 May 2007 on the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market, NV Bekaert SA (“Bekaert”) publishes the following information: Status as of 15 December 2025 Basic data Total capital: € 159 782 000.00 Total number of securities conferring voting rights: 51 315 868 shares Total number of voting rights (the denominator): 51 315 868 (one voting right per share) Rea...
Bekaert: Transparantiewetgeving
Bekaert: Transparantiewetgeving TransparantiewetgevingOpenbaarmaking conform de Wet van 2 mei 2007 Conform artikelen 15 §1 en 18 §1 van de Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in emittenten waarvan aandelen zijn toegelaten tot de verhandeling op een gereglementeerde markt maakt NV Bekaert SA (“Bekaert”) volgende informatie bekend: Toestand op 15 december 2025 Basisgegevens Totaal kapitaal: € 159 782 000,00 Totaal aantal stemrechtverlenende effecten: 51 315 868 aandelen Totaal aantal stemrechten (de noemer): 51 315 868 (één st...
IBA acquires ORA expanding its strategic leadership in Nuclear Medicin...
IBA acquires ORA expanding its strategic leadership in Nuclear Medicine Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium. This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and more personalized patient...
Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en m...
Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en médecine nucléaire Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine nucléaire, acquiert ORA, pionnier mondial de la radiochimie, basé en Belgique. Cette acquisition illustre l'engagement à long terme d'IBA dans le domaine en pleine expansion et à fort potentiel de la médecine nucléaire. Elle consolide la position d'IBA à l’avant-garde de l'innovation en oncologie de précision, p...
Galapagos Announces Topline Results from Two Phase 3-Enabling Studies ...
Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematosus study, GLPG3667 delivered numerical improvements on several secondary endpoints compared to placebo but did not achieve statistical significance in primary endpoint analysis The safety profile ...
Galapagos maakt topline resultaten bekend van twee fase 3-enabling stu...
Galapagos maakt topline resultaten bekend van twee fase 3-enabling studies met selectieve TYK2-remmer GLPG3667 bij dermatomyositis en systemische lupus erythematodes GLPG3667 bereikte het primaire eindpunt in de dermatomyositis-studie en toonde een statistisch significant klinisch voordeel en betekenisvolle verbeteringen aan op secundaire eindpunten van ziekteactiviteit in vergelijking met placebo In de studie naar systemische lupus erythematodes leverde GLPG3667 numerieke verbeteringen op voor verschillende secundaire eindpunten in vergelijking met placebo, maar bereikte het geen statisti...
SBM Offshore signs contract extension of FPSOs Mondo and Saxi Batuque
SBM Offshore signs contract extension of FPSOs Mondo and Saxi Batuque Amsterdam, December 17, 2025 SBM Offshore announces it has signed a contract extension related to the lease and operation of FPSOs Mondo and Saxi Batuque with Esso Exploration Angola (Block 15) Limited, as the Operator of Block 15, an affiliate of ExxonMobil. The extension secures ownership and operations by SBM Offshore until 2032. The agreement includes life-extension activities, for equipment replacement and refurbishment, to maintain high safety standards and ensure operational excellence throughout the contract ter...
Weekly share repurchase program transaction details
Weekly share repurchase program transaction details Amsterdam, December 17, 2025 SBM Offshore reports the transaction details related to its EUR141 million (c. US$150 million1) share repurchase program for the period December 11, 2025 through December 17, 2025. The repurchases were made under the EUR141 million share repurchase program announced on February 20, 2025 and effective from April 24, 2025. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. Information regarding the progress of the share...
SBM Offshore completes the Share Purchase Agreement with GEPetrol
SBM Offshore completes the Share Purchase Agreement with GEPetrol Amsterdam, December 17, 2025 SBM Offshore confirms it has completed the transaction related to the Share Purchase Agreement announced on June 4, 2025, for the full divestment of SBM Offshore’s equity interest in the lease and operating entities of the FPSO Aseng to GEPetrol. SBM Offshore’s sale of its participation in the unit in Equatorial Guinea is in line with its strategy to rationalize its Lease & Operate portfolio, as per other recent transactions. Corporate Profile SBM Offshore is the world’s deepwater ocean-infras...
- ING Helpdesk
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Dominic Rose
- Naresh Chouhan
Thematic - 2026 Outlook - "5 More Years" (55pgs)
For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
Proton Therapy New Standard of Care for Patients with Oropharyngeal Ca...
Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer Louvain-La-Neuve, Belgium, December 15, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11, The Lancet – one of the world’s most renowned academic journals – published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. , led by MD Anderson Cancer Center, the world’s ...
La protonthérapie, nouvelle norme de soins pour les patients atteints ...
La protonthérapie, nouvelle norme de soins pour les patients atteints d'un cancer de l'oropharynx Louvain-la-Neuve, Belgique, le 15 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, a le plaisir d'annoncer aujourd'hui que The Lancet – l'une des revues scientifiques les plus renommées au monde – a publié, le 11 décembre, une étude historique recommandant la protonthérapie comme nouvelle norme de soins pour les patients atteints d'...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.